Differentiating Factors Between Erythropoiesis-Stimulating Agents: A Guide to Selection for Anaemia of Chronic Kidney Disease

Author： Deicher R.   Hörl W.H.  

Publisher： Adis International

ISSN： 0012-6667

Source： Drugs, Vol.64, Iss.5, 2004-01, pp. : 499-509

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis

By Escudero-Vilaplana Vicente  

International Journal of Clinical Pharmacy, Vol. 35, Iss. 3, 2013-06 ,pp. : 463-468

Springer Publishing Company

Access to resources Recommend Favorite

Safety issues related to erythropoiesis-stimulating agents used to treat anemia in patients with chronic kidney disease

By Del Vecchio Lucia   Locatelli Francesco  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 923-931

Informa Healthcare

Access to resources Recommend Favorite

Management of Anaemia: A Critical and Systematic Review of the Cost Effectiveness of Erythropoiesis-Stimulating Agents

By Mei Sheng Duh  

PharmacoEconomics, Vol. 26, Iss. 2, 2008-01 ,pp. : 99-120

Adis International

Access to resources Recommend Favorite

Safety of erythropoiesis-stimulating agents in patients with end-stage kidney disease: data are safer than extrapolations

By Abraham Ivo   MacDonald Karen  

Expert Opinion on Drug Safety, Vol. 11, Iss. 6, 2012-11 ,pp. : 885-887

Informa Healthcare

Access to resources Recommend Favorite

Erythropoiesis-Stimulating Agents in Oncology

By Glaspy John A.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 6, 2008-07 ,pp. : 565-575

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite